Gilead Sciences, Inc. (NASDAQ:GILD) is Sector Gamma AS’s 5th Largest Position

Sector Gamma AS grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 475,056 shares of the biopharmaceutical company’s stock after buying an additional 30,000 shares during the quarter. Gilead Sciences accounts for about 5.1% of Sector Gamma AS’s investment portfolio, making the stock its 5th largest holding. Sector Gamma AS’s holdings in Gilead Sciences were worth $30,109,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Cooper Financial Group boosted its position in shares of Gilead Sciences by 4.3% in the 2nd quarter. Cooper Financial Group now owns 3,604 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 149 shares during the period. LeJeune Puetz Investment Counsel LLC grew its holdings in shares of Gilead Sciences by 0.6% during the 3rd quarter. LeJeune Puetz Investment Counsel LLC now owns 26,385 shares of the biopharmaceutical company’s stock worth $1,672,000 after purchasing an additional 155 shares in the last quarter. Alpha Cubed Investments LLC grew its holdings in shares of Gilead Sciences by 0.6% during the 2nd quarter. Alpha Cubed Investments LLC now owns 25,592 shares of the biopharmaceutical company’s stock worth $1,729,000 after purchasing an additional 156 shares in the last quarter. Blume Capital Management Inc. grew its holdings in shares of Gilead Sciences by 4.8% during the 2nd quarter. Blume Capital Management Inc. now owns 3,615 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 165 shares in the last quarter. Finally, Perigon Wealth Management LLC grew its holdings in shares of Gilead Sciences by 0.3% during the 2nd quarter. Perigon Wealth Management LLC now owns 51,335 shares of the biopharmaceutical company’s stock worth $3,468,000 after purchasing an additional 165 shares in the last quarter. Institutional investors own 79.91% of the company’s stock.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 5,677 shares of Gilead Sciences stock in a transaction on Monday, October 28th. The shares were sold at an average price of $63.31, for a total value of $359,410.87. Following the sale, the executive vice president now directly owns 21,521 shares in the company, valued at approximately $1,362,494.51. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Brett A. Pletcher sold 2,095 shares of Gilead Sciences stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $66.06, for a total transaction of $138,395.70. Following the completion of the sale, the executive vice president now owns 17,826 shares in the company, valued at $1,177,585.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,288 shares of company stock worth $1,108,682. 0.20% of the stock is owned by corporate insiders.

GILD stock traded up $1.42 during trading on Friday, reaching $65.38. The company had a trading volume of 4,953,000 shares, compared to its average volume of 6,639,518. Gilead Sciences, Inc. has a 52 week low of $60.32 and a 52 week high of $72.90. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.06 and a quick ratio of 2.96. The business has a 50 day moving average of $64.15 and a 200 day moving average of $65.25. The company has a market cap of $82.81 billion, a P/E ratio of 10.63, a PEG ratio of 3.47 and a beta of 1.09.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.74 by $0.01. The business had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.61 billion. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. The company’s revenue was up .1% compared to the same quarter last year. During the same quarter last year, the company posted $1.84 EPS. Research analysts expect that Gilead Sciences, Inc. will post 6.66 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.85%. The ex-dividend date of this dividend is Thursday, December 12th. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.

Several analysts have recently weighed in on GILD shares. Guggenheim set a $86.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Friday, October 25th. Citigroup set a $78.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, July 31st. Jefferies Financial Group set a $95.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Monday, July 15th. JPMorgan Chase & Co. restated a “buy” rating and set a $85.00 price target on shares of Gilead Sciences in a research report on Wednesday, July 31st. Finally, BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and an average target price of $79.27.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: Intrinsic Value

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.